Protego

Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study

– Financing led by Novartis Venture Fund and Forbion, with new investment from Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures – Renewed backing from Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research     SAN DIEGO, Calif., Dec. 1, 2025 — Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering […]